Cargando…

Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib

Anaplastic lymphoma kinase (ALK) rearrangement is an oncogene targeted with approved drugs second to epidermal growth factor receptor (EGFR) in lung cancer. Crizotinib was developed and introduced into clinical practice rapidly and successfully after the discovery of ALK rearrangement in non-small-c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niu, Fei-Yu, Wu, Yi-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427450/ https://www.ncbi.nlm.nih.gov/pubmed/25999733 http://dx.doi.org/10.2147/OTT.S64664

Ejemplares similares

Crizotinib in the treatment of non-small-cell lung carcinoma
por: Płużański, Adam, et al.
Publicado: (2013)

Role of Crizotinib in previously treated non-small-cell lung cancer
por: Gupta, Sunil Kumar
Publicado: (2014)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)

Clinical use of crizotinib for the treatment of non-small cell lung cancer
por: Roberts, Patrick J
Publicado: (2013)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice
por: Liu, Chang, et al.
Publicado: (2019)

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
por: Nishio, Makoto, et al.
Publicado: (2018)

Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib
por: Xu, Chun-wei, et al.
Publicado: (2018)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018)

Crizotinib-induced immunogenic cell death in non-small cell lung cancer
por: Liu, Peng, et al.
Publicado: (2019)

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer
por: Kang, Jin, et al.
Publicado: (2018)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
por: Liu, Chang, et al.
Publicado: (2019)

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Asai, Nobuhiro, et al.
Publicado: (2014)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
por: Ryu, Woo Kyung, et al.
Publicado: (2022)

Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
por: Guo, Liting, et al.
Publicado: (2015)

From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
por: Pirker, Robert, et al.
Publicado: (2019)

Effective treatment of MET-amplified non-small cell lung cancer patients with crizotinib: a case description
por: Tang, Mingyue, et al.
Publicado: (2023)

Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients
por: Cao, Yabing, et al.
Publicado: (2014)

The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials
por: Qian, Haili, et al.
Publicado: (2014)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2017)

Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer
por: Liu, Peng, et al.
Publicado: (2019)

Perioperative crizotinib in a patient with stage IIIB ALK-positive non-small cell lung cancer: a case report
por: Tian, Yu, et al.
Publicado: (2020)

Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer
por: Hong, Xiangchan, et al.
Publicado: (2017)

Imaging features of renal complications after crizotinib treatment for non–small-cell lung cancer: a case report
por: Chan, Wan Ying, et al.
Publicado: (2016)

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2019)

Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
por: Lu, Shun, et al.
Publicado: (2018)

Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment
por: Xu, Haiyan, et al.
Publicado: (2019)

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer: A Randomized Clinical Trial
por: Horn, Leora, et al.
Publicado: (2021)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
por: Wang, Yurong, et al.
Publicado: (2022)

Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study
por: Xing, Puyuan, et al.
Publicado: (2019)

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
por: Morcos, Peter N., et al.
Publicado: (2018)

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
por: Wei, Jiacong, et al.
Publicado: (2018)

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
por: Ma, Di, et al.
Publicado: (2019)

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
por: Mehta, Anurag, et al.
Publicado: (2020)

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer
por: Kazandjian, Dickran, et al.
Publicado: (2016)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Leprieur, Etienne Giroux, et al.
Publicado: (2016)

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
por: Sivignon, Marine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4nhnb9g2d6vjlbuu6lfq0dndlg